Evidence map›Paper›PMID 37124750›Full record

ArticleFrontiers in endocrinology2023

Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.

Jie Zhou, Wei-Ran Wang, Hui-Fang Zhang, Qi-Qi Gao, Wei-Bin Wang, Jian-Hua Zhu, Yu-Shuai Han, Jing Chen, Tong-Hui Ma, Xiao-Yan Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Molecular and clinicopathological characteristics ofHistology and histopathology · 2026
    Review
  3. Review
  4. Article
  5. Diagnostic utility ofEXCLI journal · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jie ZhouDepartment of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wei-Ran WangDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Hui-Fang ZhangDepartment of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qi-Qi GaoDepartment of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wei-Bin WangCancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jian-Hua ZhuDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Yu-Shuai HanDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Jing ChenDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Tong-Hui MaDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Xiao-Yan ZhangDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Xiao-Dong TengDepartment of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Annoroad Gene Technology (China) · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Genotyping is fundamental in papillary thyroid cancer (PTC) and helps to enhance diagnosis and prognosis and determine appropriate treatments. The phenotype-genotype association in PTC was previously studied, with Methods: We screened out non-classical PTC by excluding classical PTC from 1,059 different thyroid samples, and a total of 24 cases was obtained and described from the morphological features, which is rare in differentiated PTC. DNA/RNA sequencing was performed using 18 available samples to describe the genetic features. Results: PTC with the non-classical phenotype were characterized cuboidal to low columnar tumor cells with subtle nuclear features of PTC and without discernible nuclear elongation, concurrently with dense microfollicles, delicate papillae or solid nodules with delicate fibrovascular cores. They were associated with lymphatic vessel invasion (P<0.001) but not with a worse prognosis (P=0.791). Gene fusions were identified in 14 of 18 (77.8%) cases, including eight fusions of Conclusions: Our study retrospectively screened a large cohort of different thyroid tissue samples, and presented the histopathological and genetic features of a non-classical phenotype of PTC from 24 patients. It may contribute to diagnose in PTC, and patients of these non-classical phenotype may benefit from targeted therapy, compared to a natural patient cohort without selection.

Indexed as

Carcinoma, PapillaryThyroid NeoplasmsHumansPhenotypeProto-Oncogene Proteins B-rafRetrospective StudiesThyroid Cancer, PapillaryProto-Oncogene Proteins B-rafETV6-NTRK3gene fusionNCOA4-RETpapillary thyroid carcinomaphenotype

Identifiers

PMID37124750
PMCPMC10130378
OpenAlexW4365148903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.